Soft Tissue Sarcoma with Jonathan C. Trent, MD, PhD and Shreyaskumar R. Patel, MD: Case 1 - Episode 12
What additional options are available for durable response in this patient to stabilize her metastatic disease?
This patient with leiomyosarcoma has been treated with an anthracycline, which is the standard frontline regimen, and gemcitabine plus docetaxel, which is standard second-line regimen. This patient has also been treated with pazopanib.
An additional agent for a patient with metastatic leiomyosarcoma would be the use of trabectedin. Trabectedin has been shown to be more active than dacarbazine in leiomyosarcoma, improving the median progression-free survival from only 1.5 months to a median of 4.6 months.
CASE: Soft-Tissue Sarcoma (Part 1)
Rachel F is a 58-year-old school teacher from Roanoke, Virginia. Her medical history is notable for mild hypertension and total knee replacement in 2011
Follow-up CT scan in January 2014 showed progression at multiple sites; at the time of follow up, her ECOG performance status was 1, with renal and hepatic function within normal limits
In September of 2014 she returns for follow-up, unable to work with increasing fatigue and abdominal pain, and her CT scan was consistent with progressive disease
After 4 months of therapy, she presents with worsening abdominal pain and declining performance status